Cas9 Stable Cell Line - CNE2

The CNE2-Cas9 stable cell line is a specialized genetic model derived from the poorly differentiated nasopharyngeal carcinoma (NPC) cell line CNE2, genetically engineered to constitutively express the Cas9 nuclease. Unlike the more differentiated CNE1 cell line, CNE2 represents a more aggressive and less differentiated NPC, typically exhibiting higher metastatic potential and a worse prognosis. The stable integration of Cas9 in this context provides an efficient and standardized platform for CRISPR-mediated gene editing, ensuring high editing efficiency across the entire cell population. This system overcomes the limitations of transient transfection, such as inefficiency in difficult-to-transfect cancer cells and unstable Cas9 levels, thus providing a more reliable tool for elucidating the complex genetic mechanisms of aggressive NPC.

Applications of the CNE2-Cas9 stable cell line primarily focus on revealing the molecular driving mechanisms of NPC metastasis, drug resistance, and immune escape. For researchers performing genome-wide CRISPR screening to identify vulnerabilities in undifferentiated NPC cells, the CNE2-Cas9 cell line is a crucial tool. Scientists have used this cell line to generate targeted mutations in genes associated with cell cycle regulation, apoptosis, and signaling pathways such as Wnt/β-catenin or NF-κB. Furthermore, the CNE2-Cas9 cell line has been used to study Epstein-Barr virus (EBV) and its role in nasopharyngeal carcinoma, providing a human context for studying virus-host interactions. This cell line supports stable and high-level gene editing, making it an important resource for developing novel therapies and for preclinically validating drug targets for aggressive head and neck cancers.